Cover image of The Bio Report
(17)
Business
Investing

The Bio Report

Updated 4 days ago

Business
Investing
Read more

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Read more

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

iTunes Ratings

17 Ratings
Average Ratings
8
3
3
1
2

Sound quality lacking, but great content

By DGrande - Sep 07 2018
Read more
Can’t understand why this isn’t more popular...it’s incredibly relevant, instructive, and brings in great guests. These are the things I need to know for my team and company. 5 stars.

Good content

By Inrater - Sep 06 2018
Read more
I am a longtime investor in Biotech and find the topics and interviews extremely interesting. The sound is not that good but it really doesn’t matter when the content is interesting. I would shorten the intro jingle by 50%. Keep up the good work.

iTunes Ratings

17 Ratings
Average Ratings
8
3
3
1
2

Sound quality lacking, but great content

By DGrande - Sep 07 2018
Read more
Can’t understand why this isn’t more popular...it’s incredibly relevant, instructive, and brings in great guests. These are the things I need to know for my team and company. 5 stars.

Good content

By Inrater - Sep 06 2018
Read more
I am a longtime investor in Biotech and find the topics and interviews extremely interesting. The sound is not that good but it really doesn’t matter when the content is interesting. I would shorten the intro jingle by 50%. Keep up the good work.
Cover image of The Bio Report

The Bio Report

Updated 4 days ago

Read more

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Rank #1: Overcoming the Delivery Challenges of Gene Therapy

Podcast cover
Read more
Gene therapy represents an expanding area of potential to correct and modulate the activities of genes driving diseases. One of the major challenges these groundbreaking technologies face, though, is delivering them to where they need to go within the body to be effective. Nanogenic Solutions believes its solved the problem with its LipTide technology that marries a payload carrying-lipid with synthetic peptides that target cell suface receptors and allow DNA or RNA into the cell. We spoke to Simon Newman, director of preclinical development for Nanogenic Solutions, about the challenges of gene therapy, the LipTide technology, and what it could mean for advancing a range of RNA and DNA therapies.
Jun 01 2017
17 mins
Play

Rank #2: ALS Fight Carries Muller from Patient to Biotech CEO

Podcast cover
Read more
Bernard Muller was a successful businessman in the maritime and oil industry, but when he was diagnosed with the neurodegenerative disease ALS in 2010, he turned his entrepreneurial skills toward developing new therapies to treat the disease. Muller co-founded the world’s largest genetic research project for ALS, project MinE, and launched Treeway, a biotech company developing new therapies for ALS. As the Biotechnology Industry Organization kicks off its BIO 2015 International Convention in Philadelphia June 15, Muller is a finalist as one of the organization’s Everyday Superheroes in the pharma/biotech category. We spoke to Muller about his decision to launch Treeway, the active role he sees for patients, and why he thinks traditional approaches to drug development and clinical trial design have not served ALS patients well.
Jun 11 2015
17 mins
Play

Rank #3: Biotech Industry Moves Towards a Patent Cliff

Podcast cover
Read more
Scrutiny of drug prices around the globe is expected to exert growing pressure on the biopharmaceutical sector. EvaluatePharma, in its recently issued World Preview 2017, Outlook to 2022 says that despite consensus forecasts for worldwide drug sales hitting more than $1 trillion in 2022, it does reflect a drop from the same period last year. We spoke to Antonio Iervolino, head of forecasting for evaluate pharma, about the new report, the outlook for the sector and the potential for a new patent cliff with the advent of biosimilars.
Jul 13 2017
14 mins
Play

Rank #4: Accelerating Early-Stage Biotechs

Podcast cover
Read more
The effort to cost-effectively accelerate the development of new therapies has led to the rise of new business models that seek to provide expertise, capital, and access to professional networks that can help early-stage companies navigate pitfalls and overcome challenges. Xontogeny is a bit of a hybrid in its approach, preferring the term aggregator to accelerator or incubator. We spoke to Chris Garabedian, chairman and CEO of Xontogeny, about the company’s approach, what it looks for in the biotechs it backs, and what he’s learned from his own experience as a biotech executive that he thinks will benefit others.
Apr 18 2019
29 mins
Play

Rank #5: When Hospital Cause, Rather than Cure, Deadly Infections

Podcast cover
Read more
A growing problem with drug resistant infections acquired in hospitals is catching the eye of Consumer Reports, which has added the incidence of two common and deadly infections to their hospital ratings. The ratings come in the second part of a three-part investigation in the antibiotic crisis. We spoke to Doris Peter, director of Consumer Reports’ Health Ratings Center, about the study, what the highest rated hospitals are doing that the lower rated ones are not, and things patients can do to safeguard themselves when they face a hospital stay.
Jul 30 2015
13 mins
Play

Rank #6: Home-Brew Morphine, Dual Use Technology, and the Biologist's Repsonsibilities

Podcast cover
Read more
A recent article in Nature Chemical Biology that shows it is possible to convert sugar into morphine with genetically engineered yeast has sparked public attention over the potential illicit use of the technology and the need for regulation. The work, though, also opens up significant possibilities for producing a wide range of drugs and the discovery of new ones to treat everything from cancer to infectious diseases. We spoke John Dueber, assistant professor of bioengineering at the University of California, Berkeley and one of the authors of the study, about the work, its implications, and what role biologists need to play in regulating themselves.
May 20 2015
20 mins
Play

Rank #7: Targeting Regulators of Genes to Treat Cancer

Podcast cover
Read more
While much of the focus of drug developers looking to act on the genetic mechanisms underlying diseases has focused on the genes that code for proteins, Syros Pharmaceuticals is looking to the regulatory regions of the genome. This is the noncoding part of the genome that controls the expression of genes, turning them on or off, or modulating their level of activity. We spoke to Eric Olson, chief scientific officer of Syros Pharmaceuticals, about the company’s discovery platform, its pursuit of cancer and monogenic diseases, and the lead programs in its pipeline.
Aug 08 2019
21 mins
Play

Rank #8: Addressing the Challenge of Making Antibody-Drug Conjugates

Podcast cover
Read more
Antibody-drug conjugates marry the precise targeting of an antibody to a cytotoxic payload. That has the potential to provide a powerful treatment approach to a variety of cancers with less toxicity than systemically delivered chemotherapy. The problem has been producing large quantities of antibody-drug conjugates in a consistent manner where all the pieces are where they belong. Sutro Biopharma has developed a technology platform that allows it to precisely design and consistently manufacture these molecules. We spoke to Bill Newell, CEO of Sutro, about the promise of antibody-drug conjugates, the company’s platform technology, and its lead therapeutic candidates.
Aug 15 2019
25 mins
Play

Rank #9: Enlisting the Immune System in the Battle Against Alzheimer's

Podcast cover
Read more
Alzheimer’s disease is the sixth leading cause of death and it continues to rise. Today it is costing the U.S. healthcare system $200 billion a year and there are no therapies that prevent, halt, or reverse the disease’s progression. United Neuroscience is taking a new approach to the disease with its endobody vaccines, a class of synthetic biologics it is developing to treat Alzheimer’s and other CNS conditions. We spoke to Ajay Verma, chief medical officer of United Neurosciences, about Alzheimer’s, the company’s platform technology, and the promise of enlisting the immune system in the fight against CNS diseases.
Jun 08 2017
18 mins
Play

Rank #10: The Year in Immuno-Oncology and What to Watch in 2018

Podcast cover
Read more
It’s that time of year when we begin to look back and think ahead. Starting with this week’s interview, we begin a three-part review-preview series to discuss the year in biotech and what to look for in 2018. In 2017, there were exciting developments in the area of immune-oncology with the approval of the first Car-T therapies and Gilead’s acquisition of Kite Pharma. As the year approached the finish line, investors got to view data from a range of studies at the American Society of Hematology meeting in Atlanta, setting the stage for 2018 when data from studies looking at combinations of immunotherapies will be closely watched. We spoke to Brad Loncar, CEO of Loncar investments, about the state of immunotherapies, what caught his attention at the ASH meeting, and what he’ll be watching in 2018.
Dec 21 2017
38 mins
Play

Rank #11: Squeezing New Possibilities into Cell Therapies

Podcast cover
Read more
SQZ Biotech believes its platform technology can enable the engineering of virtually any function into any cell type allow for a new world of cell therapies to revolutionize the treatment of diseases. As its name implies, it does this by squeezing a cell to momentarily disrupt its membrane to allow it to insert a range of substances. We spoke to Armon Sharei, CEO of SQZ Biotech, about the company’s platform technology, its initial focus on oncology and auto-immune diseases, and the broad potential for this approach.
Mar 21 2019
26 mins
Play

Rank #12: Why Foresite Capital is Betting Big on the Convergence of AI and Biotech

Podcast cover
Read more
The convergence of artificial intelligence and the life sciences is promising to revolutionize the entire healthcare continuum including the way drugs are discovered, how clinical trials are conducted, the methods physicians use to diagnose patients, and how patients are monitored and treated. The life sciences investment firm Foresite Capital, armed with a new $668 million fund, is helping to bring about this change by backing innovative companies working at this nexus information technology and biotechnology. We spoke to Brett Zbar and Vik Bajaj, managing directors of Foresite, about their new fund, what constitutes a Foresite investment, and why they believe this is not just the latest fad, but a meaningful change in the way life sciences companies seek to address the challenges in all aspects of healthcare.
Aug 23 2018
28 mins
Play

Rank #13: Why Biomarkers May Be the Key to Immuno-Oncology Success

Podcast cover
Read more
Developers of cancer immunotherapies are in a race to find combinations that can distinguish their products for specific indications. Biomarkers, which have played an essential role in the development of targeted therapies, have proven a much more complex challenge in the realm of immuno-oncology. Nevertheless, biomarkers may be the key to winning the competitive battles in immuno-oncology. We spoke to Rachel Laing, managing partner of Bionest Partners, about the role for biomarkers in immuno-oncology, why immuno-oncology companies have much at stake in the hunt for biomarkers that can better select patients for their therapies, and the role biomarkers will play in the move toward real-time oncology.
May 10 2018
26 mins
Play

Rank #14: Harnessing the Immune System to Diagnose and Treat Cancer

Podcast cover
Read more
Anixa Biosciences is harnessing the immune system to both diagnose and treat cancer. It recently announced a licensing agreement with the Cleveland clinic for a novel breast cancer vaccine that is being developed for both therapeutic and prophylactic use. It’s lead candidate is a CAR-T cell therapy in development for ovarian and other solid tumors. We spoke to Amit Kumar, president and CEO of Anixa, about the company’s strategy to pursue both therapeutic and diagnostic products, its partnerships with leading research institutes, and its development strategy going forward.
Aug 01 2019
3 mins
Play

Rank #15: Why Drug Companies May Soon Become Health Technology Companies

Podcast cover
Read more
The convergence of technology and life sciences, changing consumer behavior, and increasing pricing pressures on drug and device makers are forcing these companies to rethink business models and how they derive value from their products, according to a new EY Progressions 2018 report. The report argues that life sciences companies will no longer be able to rely exclusively on product-centric innovations, which face diminishing returns as health systems wrestle with cost constraints. We spoke to Pamela Spence, EY global life sciences industry leader, about the report, what a growing trend in collaborations between technology and healthcare companies may say about where the industry is heading, and why the future of life sciences companies may be as health technology companies.
Mar 15 2018
24 mins
Play

Rank #16: The Outlook for Biotech in 2018

Podcast cover
Read more
We conclude our biotech review-preview series with our final installment this week as we take a look at the year ahead as the industry readies for the JPMorgan Healthcare Conference. We spoke to Jon Gardner, U.S. News Editor for EP Vantage, about the EP Vantage 2018 Preview(http://bit.ly/2CT2RDP), the outlook for big-value drug launches, and whether dealmaking or clinical success will drive stock prices in 2018. As a note, this podcast was recorded prior to Spark Therapeutics announcement of its pricing for its gene therapy Luxturna.
Jan 04 2018
19 mins
Play

Rank #17: Building Better Drugs for Psychiatric Disorders by Targeting the Causes

Podcast cover
Read more
The Johns Hopkins University School of Medicine and the Salk Institute for Biological Studies are leading a $15.4 million effort to develop new systems for quickly screening libraries of drugs for potential effectiveness against schizophrenia and bipolar disorder. The National Institute of Mental Health is funding the work. We spoke to Hongjun Song, professor of neurology and neurosciences at the Johns Hopkins University School of Medicine, about the effort, the challenges of understanding the underlying biological mechanism of these disorders, and how the consortium expects to change the development of drugs to treat mental illnesses.
Sep 15 2016
17 mins
Play

Rank #18: A Look at the Year That Was in Biotech

Podcast cover
Read more
The year 2014 was one for the record books for the biotech industry. In part one of a two-part podcast, we take a look back at the year that was with Adam Feuerstein, senior columnist for TheStreet.com. Feuerstein discusses the growing controversy over drug pricing, the newsmakers of 2014, and lessons from the Dendreon bankruptcy.
Dec 24 2014
15 mins
Play

Rank #19: Curing Cancer with Math

Podcast cover
Read more
The promise of precision medicine to provide more effective and safer cancer therapies that target the genetics driving each patient’s disease has been hindered by the lack of understanding of the specific genetic alterations underlying many cancers. Elana Fertig thinks math can solve that problem. Fertig, with a nod to the algorithm Netflix uses to help recommend movies users might like, is working to identify the genes that drive an individual’s cancer. Fertig, assistant professor of Oncology Biostatistics and Bioinformatics at Johns Hopkins Kimmel Cancer Center, discussed the proliferation of genetic data relating to cancer, how researchers may be able to capitalize on that, and how such an approach may also bring a new understanding of why patients suffer relapses and develop resistance to cancer therapies.
Apr 27 2017
18 mins
Play

Rank #20: Attacking IBD Through a Novel Pathway

Podcast cover
Read more
Current therapies for autoimmune diseases represent a $100 billion market, but available drugs often provide limited benefits to patients or cause problematic side effects. Landos Biopharma is targeting the area of autoimmune diseases with an initial focus on inflammatory bowel disease by pursuing therapies that target a novel pathway. We spoke to Landos founder and CEO Josep Bassaganya-Riera, about IBD, why new therapies are needed, and the approach Landos is taking.
Jan 17 2019
19 mins
Play

Similar Podcasts